Ipsen
Ipsen SA engages in the research, development, manufacture, and sale of pharmaceutical products worldwide.
Launch date
Employees
Market cap
€8.7b
Enterprise valuation
€8.5b (Public information from Sep 2024)
Share price
€109 IPN.PA
Boulogne-Billancourt Île-de-France (HQ)
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 2.7b | 2.7b | 3.2b | 3.3b | 3.5b | 3.7b | 4.0b |
% growth | - | 2 % | 15 % | 5 % | 5 % | 7 % | 7 % |
EBITDA | 958m | 1.1b | 1.2b | 643m | 1.2b | 1.3b | 1.3b |
% EBITDA margin | 36 % | 40 % | 38 % | 19 % | 34 % | 34 % | 34 % |
Profit | 548m | 647m | 649m | 644m | 592m | 706m | 784m |
% profit margin | 20 % | 24 % | 21 % | 19 % | 17 % | 19 % | 20 % |
EV / revenue | 2.3x | 2.5x | 2.5x | 2.7x | 2.5x | 2.2x | 1.9x |
EV / EBITDA | 6.4x | 6.2x | 6.5x | 13.8x | 7.2x | 6.3x | 5.4x |
R&D budget | 406m | 424m | 445m | 619m | - | - | - |
R&D % of revenue | 15 % | 15 % | 14 % | 19 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | £22.0m | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about Ipsen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by Ipsen Jan 2023
ACQUISITION by Ipsen Feb 2019
ACQUISITION by Ipsen Jun 2008
ACQUISITION by Ipsen Jun 2022
exited
ACQUISITION by Ipsen Jul 2013
ACQUISITION by Ipsen Feb 2015
ACQUISITION by Ipsen Jun 2015